

# Phenotypic And Molecular Characterization of Extended- Spectrum B-Lactamase Producer *Serratia Marcescens* Isolated from Surgical Wound Infections

Nada Khairi Younus

Department of Pharmacy, Alnoor University Collage, Mosul, Iraq

Email: [nada.khairi@alnoor.edu.iq](mailto:nada.khairi@alnoor.edu.iq)

## Abstract

**Introduction:** *Serratia marcescens* is a one type of Extended-Spectrum Beta-Lactamases (ESBLs) are the major cause of resistance to beta-lactam antibiotics such as amoxicillin, cefixime, cefotaxime, ceftazidime, ceftriaxone, piperacillin tetracycline and trimethoprim-sulfa. CTX-M and SHV but not TEM genes were present in *Serratia marcescens* resist pathogenic form. **Aim:** To determine the Phenotypic and molecular characterization of Extended- spectrum  $\beta$ -lactamase producer *Serratia marcescens* isolated from surgical wound infections by detection three genes resist to different types of antibiotics. **Methodology:** The present study was carried out from June 2020 to June 2022 in the department of pharmacy, microbiology lab, Al-noor University College. Eighty-six 86 out of 158 wound swabs samples were extended- spectrum  $\beta$ -lactamase producer *Serratia marcescens*. The isolates were collected from patients suffering from contaminated wound surgery and studied at Al-Noor University collage laboratories by using morphological, culture, manual biochemical identification method using API 20E strip test and molecular identification by PCR-based technique. **Results:** All patients had signs of wound contamination like redness around wound, swelling of wound area, pus and fluid drainage from the incision area after surgery. ESBL genes were detected by PCR method among eighty-six (54.4%) swabs which contain pathogenic *Serratia marcescens* bacteria and phenotypically confirmed ESBL producers. The rest seventy-two (45.5%) phenotypically confirmed non-ESBL producers. The genes that interested in this study were, bla TEM (0%), followed by bla SHV (10.4%), and bla CTX-M (89.5%). The patterns of antimicrobial resistance for isolates under study showed susceptible to amoxicillin and meropenem while they resist to, Cefotaxime, Ceftriaxone, and Gentamycin **Conclusion:** In the present study, it was concluded that antimicrobial drugs such as Amoxicillin, Amikacin and meropenem should be highly recommended for the treatment of pathogenic *S. marcescens* resist strains as appropriate choice; and definitive identification of ESBL genes by molecular detection is the best and rapid diagnosing technique which is the key to control and management the surgical wound infection.

**Keywords:** Phenotypic – Genotypic - Extended spectrum  $\beta$ -lactamase ESBL - *Serratia marcescens*

## 1. Introduction

*Serratia* species, in particular *Serratia marcescens*, are one of gram-negative, motile, facultative anaerobic bacteria. *S. marcescens* and other members of the genus was first described in 1819, they are widespread in the environment, but are not a common component of the human fecal flora. These bacteria classified in the ethic group Klebsiella and the large family Enterobacteriaceae [4]. Some strains of *S. marcescens* are capable of producing a pigment which is called prodigiosin, it's ranges from dark red color to pale pink depending on the period of the colonies which aid us for easier identification. *Serratia* are capable of thriving in diverse environments, like water, soil, and the digestive tracts of various animals [5, 6]. The organisms in this genus, particularly *S. marcescens*, were long thought to be nonpathogenic but over the last 50 years, *Serratia marcescens* has become an important cause of nosocomial infections. Much evidence was reported to explain the ability of *Serratia marcescens* to cause infection

like utilize a wide range of nutrients so can survive and grow under extreme conditions, like in disinfectants, antiseptics and distilled water, also can grow at 37°C, but it can grow in temperatures that range from 5-40 °C. *Serratia marcescens* grow in pH levels that range from 5 to 9[1]. *Serratia* species appear to be common environmental organisms, and this helps to explain the large number of nosocomial infections due to these bacteria. Since many nosocomial infections are caused by multiply antibiotic-resistant strains of *S. marcescens*, this increases the danger to hospitalized patients, and hospital personnel should be vigilant in preventing nosocomial outbreaks due to this organism. Additionally, *Serratia* species may harbor multidrug resistance mechanisms that can complicate treatment decisions [7]. *S. marcescens*, and probably other species in the genus, carry several antibiotic resistance determinants and are also capable of acquiring resistance genes. *S. marcescens* is usually identified well in the clinical laboratory by 16S rRNA gene sequencing which enable better identification

of some of the less common *Serratia* species [3]. Some of the *S. marcescens* strains isolated from patients were an ESBL producer. ESBL producers have most commonly been documented among *Klebsiella pneumoniae* and *E. coli* strains and less commonly among other members of the family Enterobacteriaceae, such as *Serratia* species [12]. Wilke et al in 2005 reported that  $\beta$ -lactams which inhibit the cell wall biosynthesis, remained the first-line defense against bacterial infections for over 20 years, before resistant bacteria appeared in clinical practice. Resistance to this class of drugs can be the result of antibiotic target site alteration, prevention of antibiotic access by altered permeability or forced efflux, or antibiotic degradation [13]. Naturally occurring chromosomally located  $\beta$ -lactamases are quite common in Gram-negative bacteria; likely evolved from penicillin-binding proteins, when produced in small quantity they do not significantly contribute to antibiotic resistance. It was the appearance of the first plasmid-mediated  $\beta$ -lactamase TEM-1. This phenomenon was reported in 1960s. Ever since, Medeiros in 1997 improve the fact that the introduction of new natural or synthetic drugs to replace old ones in an attempt to limit the insurgence of antibiotic resistant bacteria triggered a chain reaction providing bacteria with a constant selective pressure driving the expansion of different resistance mechanisms [14,15]. The most clinically significant extended spectrum  $\beta$ -lactamases (ESBL) variants. i.e., CTX-M-, TEM-, and SHV- type enzymes [16].

The clinical sign of *Serratia* wound infection characterized by pus with drainage, bad smell coming from the wound, fever, chills, redness and pain or sore to touch. The surgeon is always noticed that a surgical wound infection can be developed at any time from 2-3 days after surgery until the wound has visibly healed (need 2-3 weeks to several months after operation) Doctors call these infections surgical site infections (SSIs) because they occur on the part of the body where the surgery took place. If you have surgery, the chances of developing an SSI are about 1% to 3% [9]. Many papers improved that the most important causative agent for bacteremia among patients is *S. marcescens* (the antibiotic resistant strains) to ampicillin, cefazolin, cephalothin and cefuroxime but sensitive to carbapenem, trimethoprim/sulfamethoxazole, ceftazidime, ceftazidime, ceftriaxone, ceftazidime, cefotetan, aztreonam, ticarcillin/clavulanate, and ciprofloxacin [10]. In this study we focused on surgical wound samples to isolate pathogenic *Serratia marcescens* strains collected from different infection sites of hospitalized patients in Al-Salam hospital of Mousl in Iraq.

## 2. Materials and Methods

### 2.1 Sample collection and biochemical tests

One hundred fifty-eight swabs were collected from hospitalized patients (male, female, and adults) from

Al-Salam hospital in Mousl city, Iraq, at the period in 2020 to 2022. A total of 86 strains of *S. marcescens* were isolated from patient wounds after surgery. Clinical isolates were evaluated using conventional laboratory techniques for culture, isolation, purification and manual biochemical identification method using API 20E strip test to get accurate identifications based on extensive databases and are standardized, easy-to-use system (BIOMERIEUX)[8].

### 2.2 Molecular identification

Traditional PCR technique were used for detect the presence of *S. marcescens* from pus wound swabs. Primers for the detection of *S. marcescens* 16S rRNA were designed and specificity tested.

### 2.3 Antimicrobial agents

Antibiotic susceptibility profiles were done by using a standard disk diffusion method recommended by the NCCLS [11].

### 2.4 Molecular identification for resist genes

Extended-spectrum  $\beta$ -lactamases (ESBLs) including TEM, SHV, and CTX-M are the predominant types that confer resistance to beta-lactam group of antibiotics.

Genomic DNA has been isolated using a Genomic DNA purification kit (Geneaid, Thailand) according to the manufacturer's protocol. Molecular detection of ESBLs-encoding genes (*bla*<sub>CTX-M</sub>, *bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>) was performed using PCR based technique. The primers were used to amplify the ESBLs-encoding genes listed in Table 1.

PCR was carried out in 50  $\mu$ l PCR volumes containing 20 ng of template DNA, 0.5 mM of dNTPs, 1.25  $\mu$ M of each primer for 16S rRNA, and for (SHV, TEM, and CTX-M antibiotics resist genes) and 3  $\mu$ l of Taq polymerase in 1 $\times$  PCR buffer. Amplification of DNA was performed in master cycle, and band for *Serratia marcescens* at 870 bp was detected with cycling parameters and primers used as described in Table 2 [17, 18]. Then in 1% agarose gel containing 25  $\mu$ g of ethidium bromide in tris-EDTA buffer PCR products were analysed. DNA ladder 100bp was included in each run.

## 3. Results

During this study, patients with signs of wound contamination after surgery had been grouped in (A, B, and C). [Table 2]. Since no data have been documented regarding the prevalence of pathogenic ESBL *Serratia marcescens* in our region, this study was designed to isolate, determine and identify phenotypes and genotypes of this bacterium in our geographical region, in Mousl.

The antimicrobial susceptibilities of *S. marcescens* clinical isolates are characterized in Table 3. The majority of isolates were susceptible to Amikacin (100%), meropenem and gentamycin (99%), levofloxacin (95%), Aztreonam (51%). The rest of antibiotics like Amoxicillin, cefixime, cefotaxime, ceftazidime, ceftriaxone, piperacillin, tetracycline

and trimethoprim-sulfa all shows zone of inhibition on Mueller Hinton Agar media (MHA). In this study, database showed 86 out of 158 bacterial isolates were extended- spectrum  $\beta$ -lactamase producer *Serratia marcescens* which confirmed phenotypically. ESBL genes were detected by PCR method among these eighty six (54.4%) pathogenic *Serratia marcescens* bacteria. The rest seventy two (45.5%) phenotypically confirmed non-ESBL producers. Out of the three beta-lactamase (bla) gene studied, bla TEM (0%), followed by bla SHV (10.4%) , and bla CTX-M (89.5%), Table 4.




Figure 2: Gel picture of amplified products CTX-M, SHV genes of *Serratia marcescens* detection isolates band 1025 and 977 bps respectively M: DNA Ladder of 100 bps.





Figure 1: Gel picture of amplified products 16S rDNA *Serratia marcescens* detection isolates band 870 bps in 1, 2, 3, and 4. M: DNA Ladder of 100 bps.

Table 1: Cycling parameters and primers used in master cycle

Genes	Primers used Sequences(5'-----3')	Polymerase Chain Reaction Conditions	Amplicon size(bp)	References
16 S rRNA	16s rDNA-F 5'TAGGGAAGATAATGACGG 3'16s rDNA-R 5'CCTCTATCCTCTTTCCAACC3'	1min at 94°C, 30s at 55°C,1 min at 72°C and number of denaturation cycle repeated to 30 cycles.	870	Sambrook and Russel (2007)
SHV	F- 5-GCCGGGTATTCTTATTTGTCGC-3R-5-TCTTCCGATGCCGCCGCCAGTCA-3	5 min at 94°C and 32 cycles of amplification consisting of 30s at 94°C, 30s at 54°C, and 1 min at 72°C, with 10 min at 72°C for final extension	977	Mulvey et al.,2011
TEM	F-5-CGCTCATGAGACAATAACCCTG-3R-5-GGATCTTCACCTAGATCCTT-3	5 min at 94°C and 32 cycles of amplification consisting of 30s at 95°C, 1 min at 54°C, and 2 min at 72°C, with 5 min at 72°C for final extension	1000	Mulvey et al.,2011
CTX-M	F-5-TCGTCTCTTCCAGAATAAGG-3R-5-AAGGAGAACCAGGAACACG-3	5 min at 94°C and 32 cycles of amplification consisting of 30s at 95°C, 1min at 54°C, and 2 min at 72°C, with 5 min at 72°C for final extension	1025	Schneider et al.,2009

Table 2: Information on the antibiotics resist genes of *Serratia marcescens* isolated from 86 wound swabs

Patients	Age(years) (gender)	No. of isolates	specimens	PCR for			ESBL
				bla CTX-M	blaTEM	blaSHV	
Group A	Rang (25-50) F	39	Surgical wound	+	-	+	+
Group B	Range (32- 55) M	47	Surgical wound	+	-	+	+
Group C	Less than 15 years old	72	Surgical wound	+	-	+	-

M, male; F, female; PCR, polymerase chain reaction; CTX-M, TEM, and SHV, resist genes; bla , beta-lactam genes.

Table 4: Distribution of ESBLs encoding genes among isolates Gene percentage

bla SHV	9 (10.4%)
bla TEM	0 (0%)
bla CTX-M	77(89.5%)

Table 3: Antibiograms pattern of *Serratia marseciens* isolates towards antibiotics

Antibiotics	RResistance %	IIntermediate %	S Sensitive %
Cephalosporins group			
Ceftazidime	72(83.7%)	4(4.6%)	10(11.6%)
Ceftriaxone	70(81.3%)	2(2.3%)	14(16.2%)
Pipracillin	2(4%)	42(48.8)	42(48.8%)
Meropenem	0(0%)	1(1.1%)	85(98.8%)
Amoxicillin	0(0%)	0(0%)	86(100%)
Aminocyclcosides group			
Amikacin	3(3.4%)	0(0%)	83(96.5%)
Aztreonam	21(24.4%)	22(25%)	43(50%)
Gentamycine	24(48%)	5(5.8%)	57(66.2%)
Fluoroquinolones group			
Levofloxacin	4(4.6%)	20(23.2%)	62(72%)
Trimethoprim/sulfamethoxazole	9(10.4%)	0(0%)	77(89.5%)

## 4. Discussion

*Serratia marcescens* belongs to family, Enterobacteriaceae [4] and is known source of Hospital acquired infection in world and also in Mousl/Iraq. The human get the infection by this type of bacteria in form of exogenous but not in form of endogenous sources. *Serratia marcescens* is a source of hospital acquired infection (HAI), common environmental organisms [7] infect human and colonise the wounds. Such colonized patients remain at risk because of new resist strains of *Serratia marcescens* that had been appeared. We here present the first study that detects *Serratia marcescens* resist strains from patient's wounds after surgeries in Mousl. Yadav and chauhan in 2016 improved that ESBL- producing bacteria including *S. marcescens* are a significant issue in management of specific bacterial diseases in hospitals if there isn't a miss use of antibiotics and there is regular use of antibiotics [19]. So, in this work we focused on this type of bacteria that produce  $\beta$ -lactamase enzymes that work by hydrolysing  $\beta$ -lactum ring of  $\beta$ -lactum antibiotics leading to inactivate them [20], have antimicrobial resist mechanism and cause HAI.

Findings of disk diffusion method revealed that most isolates of *Serratia marcescens* were highly resist to  $\beta$ -lactum antibiotics, especially Ceftazidime and Ceftriaxone. This type of resistance gives an indicator that these isolates can be considered as ESBL producers. Early detection of such types of these isolates in laboratories has significant importance for the proper treatment patients' wounds; minimize infection and control, especially when the facilities for molecular characterization are not available. In my city, many clinical laboratories follow CLSI guidelines and its implementations to control the spread of antimicrobials resistant isolates especially ESBL producers but it seems this protocol were not applied in hospitals for many years.

Finding of molecular PCR method revealed that there are two significant groups of *Serratia marcescens*, ESBL group and non ESBL group, and we found that the CTX-M with 89.5% was dominant among ESBL group resist isolate compared with SHV 10.4%, while TEM gene showed 0%. Many other studies on *Serratia marcescens* clinical isolates showed mixed results [21, 22]. The wound isolates in our setting, TEM which is not found among other two resist types show different results between our study and those of other authors from other countries indicated that the prevalence and type of ESBL genes may vary from one geographical region to another. Some other types of *Serratia marcescens* pathogenic strains lacked TEM like our study. And were highly sensitive to Meropenem 98.8%, Amoxicillin 100% and Amikacin 96.5% which can be highly dependent used in health care setting in our community. The most right explanation of our results, the expression of  $\beta$ -lactamase genes depends upon the environmental conditions such as presence of antibiotics, and gene presence does not

necessarily indicate its expression, i.e there are some "hidden ESBL"[23,24]. Strains of *Serratia marcescens* that lacked TEM, SHV, and CTX-M genes may have actually been negative or might have carried "hidden gene" for ESBL production.

## 5. Conclusion

The results of this study highlight the value of using Meropenem, Amoxicillin and Amikacin as first choice of drug to treat *Serratia* pathogenic wound infection in hospital setting. Metallic surgical tools and other hospital surrounding equipment can be a good source of infection if not used aseptically "exogenous form". An appropriate antimicrobial therapy can only be started timely with the early detection of ESBLs and be useful depending on phenotypic and genotypic laboratory methods. Phenotypic methods for diagnosis of pathogenic strains are widely dependable in our clinical laboratories. The early diagnosis of ESBL producing strains will also help to establish and implement a strict infection control policy to stop the spread of ESBL *S.marcescens*, the important pathogenic bacteria that cause HAI hospital acquired infection among patients with wound infections.

## 6. Acknowledgment

We wish to thank AL-Salam hospital staff for supporting us during the study period. We are also thankful to the Al-noor University Collage Dean of this institute and their technical staff for powering necessary helping hand.

## References

- Ofonime Mark Ogba<sup>1</sup>, Baki Idasa Mandor<sup>2</sup>, Helena Martin Omang<sup>2</sup>
- Antibiotic susceptibility pattern of *Serratia marcescens* isolates from wound infections in a tertiary health institution in Calabar, Nigeria
- Yu, W.L., Lin, C.W., Wang, D.Y. *Serratia marcescens* bacteremia: clinical features and antimicrobial susceptibilities of the isolates. *Journal of microbiology, immunology, and infection*, Volume 31, Issue 3, Sep 1998, Pages 171-179.
- Mahlen SD. *Serratia* Infections: from Military Experiments to Current Practice. *Clinical Microbiology Reviews* 2011; 24(4): 755–791.
- Donnenberg MS, Enterobacteriaceae, Mandell GL, Bennett JE, Dolin R. eds. *Principles and Practice of Infectious Diseases*. 7th. Philadelphia, Pa: Churchill Livingstone – Elsevier. 2010; 2:2815-2833.
- Seegers H, Fourichon C, Beaudeau F. Production Effects Rated to Mastitis and Mastitis Economics in Dairy Cattle Herds, *Veterinary Research*, 2003; 34:475-491.
- Quinn PJ, Markey BK, Carter ME, Donnelly WJC, Leonard FC. *Veterinary Microbiology and Microbial Disease*, ed. London: Blackwell Science, 1994; 1:465-473.
- R Moehring, S Mahlen Infections due to *Serratia* species Waltham, MA.(accesat in Ianuarie 2015),

2015.

KENNETH E. ALDRIDGE\* AND RONDY L. HODGES  
Correlation Studies of Entero-Set 20, API 20E, and  
Conventional Media Systems for Enterobacteriaceae  
Identification JOURNAL OF CLINICAL  
MICROBIOLOGY, Jan. 1981, p. 120-125 Vol. 13.

Surgical Site Infections | Johns Hopkins Medicine.

Richard I. Haddy, MD; Barbara L. Mann, PhD; Dipak  
D. Nadkarni, DO; Rafael F. Cruz, MD; Daniel J.  
Elshoff, MD; Francisco C. Buendia, MD; Theresa A.  
Domers, MD; and Anne Marie Oberheu, MD  
Nosocomial Infection in the Community Hospital:  
Severe Infection Due to *Serratia* Species. The Journal  
of Family Practice, Vol. 42, No. 3(Mar), 1996.

National Committee for Clinical Laboratory  
Standards. 2000. Performance standards for  
antimicrobial disk susceptibility test, 7th ed. NCCLS  
document M2-A7. National Committee for Clinical  
Laboratory Standards, Villanova, Pa.

Antimicrobial resistance with focus on beta-lactam  
resistance in gram-negative bacilli. Pitout JD,  
Sanders CC, Sanders WE Jr Am J Med. 1997 Jul;  
103(1):51-9.

Beta-lactam antibiotic resistance: a current structural  
perspective. Wilke MS, Lovering AL, Strynadka NC  
Curr Opin Microbiol. 2005 Oct; 8(5):525-33.

Penicillinase synthesis controlled by infectious R  
factors in Enterobacteriaceae. Datta N,  
Kontomichalou P Nature. 1965 Oct 16;  
208(5007):239-41

Evolution and dissemination of beta-lactamases  
accelerated by generations of beta-lactam  
antibiotics. Medeiros AA Clin Infect Dis. 1997 Jan; 24  
Suppl 1():S19-45.

Epidemiological expansion, structural studies, and  
clinical challenges of new  $\beta$ -lactamases from gram-  
negative bacteria. Bush K, Fisher JF Annu Rev  
Microbiol. 2011; 65():455-78.

Mulvey, M. R., Grant, J. M., Plewes, K., Roscoe, D.,  
Boyd, D. A. 2011. New Delhi Metallo  $\beta$ -Lactamase in  
*Klebsiella pneumoniae* and *Escherichia coli*, Canada.  
Emerging Infectious Diseases, 17(1):103–106.

Schneider, I., Queenan, A. M., Markovska, R.,  
Markova, B., Keuleyan, E., Bauernfeind, A. 2009.  
New Variant of CTX-M-Type Extended-Spectrum  $\beta$ -  
Lactamases, CTX-M-71, with a Gly238Cys  
Substitution in a *Klebsiella pneumoniae* Isolate from  
Bulgaria. Antimicrobial Agents and Chemotherapy,  
53(10):4518–4521.

Yadav, R. R., Chauhan, P. B. 2016. The detection of  
Extended Spectrum Beta-Lactamases (ESBLs)  
producing *Escherichia coli* isolated from clinical  
samples. International Journal of Advanced Research  
in Biological Sciences, 3(5):9–15.

Wilke, M. S., Lovering, A. L., Strynadka, N. C. 2005.  
 $\beta$ -Lactam antibiotic resistance: a current structural  
perspective. Current Opinion in Microbiology,  
8(5):525–533.

Rezende, G. S. 2019. Phenotypic and molecular  
characterization of antimicrobial susceptibility in  
*Serratia marcescens* isolated from patients in a  
tertiary hospital in the state of Tocantins. Master

dissertation.

Monteros, L. E. D. L., Silva-Sanchez, J., Jiménez, L.  
V., Rojas, T., Garza-Ramos, U., Valverde, V. 2008.  
Outbreak of Infection by Extended Spectrum  $\beta$ -  
Lactamase SHV-5-Producing *Serratia marcescens* in a  
Mexican Hospital. Journal of Chemotherapy,  
20(5):586–592.

Eftekhari F, Rastegar M, Golalipour M, Mansour  
Samaei N. Detection of extended spectrum  
beta-lactamases in urinary isolates of *Klebsiella*  
*pneumoniae* in relation to *BlaSHV*, *BlaTEM*, *BlaCTX-M*  
gene carriage. Iran J Public Health 2012;41:127-32.

Poulou A, Grivakou E, Vrioni G, Koumaki V, Pittaras  
T, Pournaras S, et al. Modified CLSI  
extended-spectrum  $\beta$ -lactamase (ESBL) confirmatory  
test for phenotypic detection of ESBLs among  
Enterobacteriaceae producing various  $\beta$ -lactamases.  
J Clin Microbiol 2014;52:1483-9.